Trial Profile
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 04 Apr 2022 Planned primary completion date changed from 31 Dec 2020 to 23 Feb 2023.
- 15 Sep 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.